Protox Therapeutics Inc., of San Diego, completed dosing of the second cohort in its transrectal study of PRX302 for the treatment of benign prostatic hyperplasia. PRX302 is a genetically engineered version of the pore forming protein proaerolysin designed to disrupt membrane integrity in prostate cells.